2025-12-25 - Analysis Report
Here's an analysis of Natera Inc. (NTRA) based on the provided data.

**0. Overview**

Natera Inc. is a genetic testing company focused on non-invasive prenatal testing (NIPT) and cancer diagnostics.

**1. Return Rate Comparison and Alpha/Beta Analysis**

*   **NTRA Cumulative Return:** 137.67%
*   **VOO (S&P 500) Cumulative Return:** 101.15%
*   **Divergence:** 36.5 (Relative Divergence: 47.5)

**Analysis:** NTRA has significantly outperformed the S&P 500, resulting in cumulative return divergence of 36.5%. The relative divergence of 47.5 indicates that this outperformance is near the middle of its historical range compared to the S&P 500.

**Alpha/Beta Analysis Table:**

|            | CAGR    | MDD    | Alpha   | Beta   | Cap(B) |
| ---------- | ------- | ------ | ------- | ------ | ------ |
| 2015-2017  | -10.0%  | 70.1%  | -34.0%  | -0.2   | 1.3    |
| 2016-2018  | 22.0%   | 80.0%  | 6.0%    | 0.1    | 2.0    |
| 2017-2019  | 50.0%   | 80.0%  | 28.0%   | 1.0    | 4.8    |
| 2018-2020  | 186.0%  | 80.5%  | 163.0%  | 1.1    | 14.1   |
| 2019-2021  | 96.0%   | 80.5%  | 49.0%   | 1.6    | 13.2   |
| 2020-2022  | -77.0%  | 80.5%  | -76.0%  | 0.1    | 5.7    |
| 2021-2023  | -194.0% | 76.6%  | -195.0% | -1.1   | 8.9    |
| 2022-2024  | 8.0%    | 76.6%  | -13.0%  | -1.2   | 22.4   |
| 2023-2025  | 165.0%  | 76.6%  | 99.0%   | 0.1    | 32.9   |

*   **CAGR:** The Compound Annual Growth Rate shows high volatility, ranging from deeply negative to strongly positive, indicating a growth company with fluctuating fortunes.
*   **MDD:** The Maximum Drawdown is consistently high, indicating significant risk.
*   **Alpha:**  The Alpha value varies greatly, suggesting periods of significant outperformance and underperformance relative to its benchmark.
*   **Beta:** The Beta value fluctuates but mostly around 1, indicating the stock generally moves in line with the market, although the more recent Beta values are negative, suggesting the opposite.

**2. Recent Stock Price Fluctuations**

*   **Current Close:** 231.96
*   **Last Market:** Price 235.54, Previous Close 235.4, Change 0.06
*   **5-day SMA:** 227.60
*   **20-day SMA:** 234.50
*   **60-day SMA:** 203.50

**Analysis:** The 5-day SMA is below the 20-day SMA, which is below the 60-day SMA. This suggests a possible recent downward trend after a longer term uptrend.

**3. Technical Indicators**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment)
*   **RSI:** 42.84 (Neutral, neither overbought nor oversold)
*   **PPO:** -1.26 (Slightly negative, indicating potential short-term weakness)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (4 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent Relative Divergence Change:** -0.1 (Short-term decline)
*   **Expected Return:** -49.9% (Long-term underperformance relative to S&P 500)

**Analysis:** The MRI suggests a medium level of investment risk. The RSI is neutral. The negative PPO and recent decline in relative divergence suggest short-term weakness. The very negative expected return is a significant warning signal.

**4. Recent News & Significant Events**

*   Several articles highlight analyst optimism (Canaccord Genuity raising price target) and positive coverage (3 Reasons We’re Fans of Natera).
*   One article mentions a cell-free DNA company presenting at a health conference, which directly relates to Natera's core business.
*   The news about institutional investment (Orion Porfolio Solutions buying shares) could be a positive sign.

**Analysis:** Recent news appears positive overall, with analyst upgrades and positive viewpoints despite the weak stock performance.

**4-2. Analyst Opinions**

*   **Consensus:** Strong Buy (~1.47)
*   **Target Price:** Average $246.26, High $285.00, Low $186.00
*   **Recent Rating Changes:** Not provided, but the consensus suggests positive sentiment.

**Analysis:**  Analysts are generally very optimistic about Natera, with a strong buy consensus and a target price significantly above the current price. However, the range of target prices is wide, indicating some uncertainty.

**5. Recent Earnings Analysis**

| 날짜       | EPS   | 매출     |
| ---------- | ----- | -------- |
| 2025-11-07 | -0.64 | 0.59 B$  |
| 2025-08-08 | -0.74 | 0.55 B$  |
| 2025-05-09 | -0.5  | 0.50 B$  |
| 2024-11-12 | -0.26 | 0.44 B$  |
| 2025-11-07 | -0.26 | 0.44 B$  |

**Analysis:** Natera is consistently losing money per share (negative EPS).  While revenue is growing, the losses are substantial. This is typical for growth companies investing heavily in expansion and R&D.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
| ----------- | -------- | ------------- |
| 2025-09-30  | $0.59B  | 64.91%        |
| 2025-06-30  | $0.55B  | 63.41%        |
| 2025-03-31  | $0.50B  | 63.12%        |
| 2024-12-31  | $0.48B  | 62.94%        |
| 2024-09-30  | $0.44B  | 61.79%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE        |
| ----------- | --------- | ---------- |
| 2025-09-30  | $1.25B   | -6.99%     |
| 2025-06-30  | $1.25B   | -8.10%     |
| 2025-03-31  | $1.24B   | -5.40%     |
| 2024-12-31  | $1.20B   | -4.50%     |
| 2024-09-30  | $0.88B   | -3.60%     |

**Analysis:**

*   **Revenue:** Revenue is steadily increasing, which is a positive sign of growth.
*   **Profit Margin:** The gross profit margin is very high, suggesting a strong pricing position and efficient cost of goods sold.
*   **Equity:** Equity is increasing, indicating the company is building assets.
*   **ROE:** The negative Return on Equity reflects the company's current unprofitability, even with growing revenue.

**7. Comprehensive Analysis**

Natera is a high-growth, high-risk company with a positive outlook from analysts, but weak actual recent stock performance and very negative profit metrics.

**Key Takeaways:**

*   **High Growth, High Risk:**  NTRA is experiencing significant revenue growth, and has a high profit margin, which is counteracted by negative profit metrics.
*   **Analyst Optimism vs. Reality:** Despite analyst enthusiasm and positive news, the stock price has recently weakened with a very negative expected return.
*   **Unprofitability:** The company is not yet profitable, and negative EPS figures. This is a crucial factor for investors to consider.
*   **Divergent Signals:** Technical indicators present a mixed picture. The neutral RSI and negative PPO suggest caution, while the analyst consensus and some news articles paint a more optimistic view.

**Overall Recommendation:**

The data paints a conflicting picture. While analyst consensus is strong buy, the price action is weak, EPS figures are very concerning.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.